A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial
NCT ID: NCT06141811
Last Updated: 2024-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
104 participants
OBSERVATIONAL
2023-04-25
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALLO-ASC-DFU
Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-302
ALLO-ASC-DFU
Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
Vehicle sheet
Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-302
Vehicle sheet
Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALLO-ASC-DFU
Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
Vehicle sheet
Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion Criteria
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Anterogen Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ChangSik Park, MD. Ph D
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
JiUng Bak, MD. Ph D
Role: PRINCIPAL_INVESTIGATOR
Borame Medical Center
DaeWon Jun, MD. Ph D
Role: PRINCIPAL_INVESTIGATOR
Bucheon St. Mary's Hospital
YoungKoo Lee, MD. Ph D
Role: PRINCIPAL_INVESTIGATOR
Soonchunhyang University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Soonchunhyang University Hospital
Bucheon-si, Gyeonggi-do, South Korea
Bucheon ST. Mary's Hospital
Bucheon-si, Gyeonggi-do, South Korea
Asan Medical Center
Seoul, , South Korea
Borame Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
YoungKoo Lee, MD. Ph D.
Role: primary
DaeWon Jun, MD. Ph D
Role: primary
ChangSik Park, MD. Ph D
Role: primary
JiUng Bak, MD. Ph D
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALLO-ASC-DFU-304
Identifier Type: -
Identifier Source: org_study_id